Table 3 Relationship between response to anti-VEGF injections and clinical characteristics in the eyes with P.

From: Quantitative analysis of choroidal vasculature in polypoidal choroidal vasculopathy using ultra-widefield indocyanine green angiography

 

Good responders (n = 22)

Poor responders (n = 10)

P value

Univariate

Multivariate

B

Pc

B

Pc

Age, years

70.2 ± 10.0

64.6 ± 8.4

0.140a

0.937

0.138

  

Sex, n (%)

  

0.355b

0.438

0.362

  

Male

14 (63.6%)

8 (80.0%)

     

Female

8 (36.4%)

2 (20.0%)

     

Anti-VEGF agents, n (%)

  

0.056b

1.419

0.386

  

Bevacizumab

7 (31.8%)

1 (10.0%)

     

Ranibizumab

7 (31.8%)

4 (40.0%)

     

Aflibercept

8 (36.4%)

5 (50.0%)

     

Baseline BCVA, logMAR

0.55 ± 0.35

0.40 ± 0.30

0.269a

0.238

0.235

  

Baseline CMT, µm

415.40 ± 140.11

423.67 ± 112.31

0.764a

1.001

0.872

  

Choroidal hyperpermeability, n (%)

5 (22.7%)

6 (60.0%)

0.040b

5.100

0.047

1.688

0.546

SFCT, µm

291.77 ± 81.90

371.60 ± 101.17

0.016a

1.010

0.036

1.014

0.022

Haller’s layer

219.59 ± 81.22

292.90 ± 97.48

0.025a

1.010

0.047

  

Choriocapillaris-Sattler's layer

72.18 ± 24.76

78.70 ± 17.58

0.509a

1.014

0.448

  

Choroidal vascular density, %

26.58 ± 1.77

28.39 ± 1.45

0.008a

1.917

0.020

2.232

0.007

Macular region (< 3 mm)

25.44 ± 2.03

26.58 ± 2.22

0.251a

1.312

0.169

  

Near-peripheral region (3 ~ 10 mm)

25.16 ± 1.90

26.96 ± 1.61

0.009a

1.779

0.029

  

Mid-peripheral region (10 ~ 15 mm)

28.01 ± 2.38

30.11 ± 1.81

0.018a

1.622

0.030

  

Far-peripheral region (> 15 mm)

28.67 ± 1.80

30.99 ± 2.44

0.005a

1.834

0.017

  
  1. BCVA, best-corrected visual acuity; CMT, central macular thickness; PCV, polypoidal choroidal vasculopathy; SFCT, subfoveal choroidal thickness; VEGF, vascular endothelial growth factor.
  2. aMann-Whitney test, bPearson’s chi square test, cLogistic regression.
Back to article page